Receptor for advanced glycation endproducts and progressive kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 1, 2015, Pages 54-60

  Fukami, Kei ^a   Taguchi, Kensei ^a   Yamagishi, Sho Ichi ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation endproducts; High mobility group box 1; Lipopolysaccharide; RAGE; Renal disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID; CALGRANULIN; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; PROTEIN S 100; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LIGAND;

ACUTE KIDNEY FAILURE; DIABETIC NEPHROPATHY; DISEASE COURSE; GENE DELETION; GLOMERULOPATHY; HUMAN; KIDNEY AMYLOIDOSIS; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN PROTEIN INTERACTION; RENOVASCULAR HYPERTENSION; REVIEW; SEPSIS; ACUTE KIDNEY INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; GENETICS; METABOLISM; NEPHRITIS; RENAL INSUFFICIENCY, CHRONIC;

ACUTE KIDNEY INJURY; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION, RENAL; KIDNEY DISEASES; LIGANDS; LUPUS NEPHRITIS; NEPHRITIS; OBESITY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RECEPTORS, IMMUNOLOGIC; RENAL INSUFFICIENCY, CHRONIC; SEPSIS;

EID: 84918514747     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000091     Document Type: Review

References (76)

1. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267:14998-15004.
2. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267:14987-14997.
3. Hudson BI, Kalea AZ, Del Mar Arriero M, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activ ation of Rac1 and Cdc42. J Biol Chem 2008; 283:34457-34468.
4. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002; 1:1-15.
5. Gugliucci A, Menini T. The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease. Adv Exp Med Biol 2014; 824:191-208.
6. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108:949-955.
7. Sorci G, R iuzzi F, Giambanco I, Donato R. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta 2013; 1833:101-109.
8. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382:685-691.
9. Harcourt BE, Sourris KC, Coughlan MT, et al. Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int 2011; 80:190-198.
10. Matsunaga N, Anan I, Rosenberg P, et al. Advanced glycation end product is implicated in amyloid-related kidney complications. Scand J Clin Lab Invest 2005; 65:263-271.
11. Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14:946-952.
12. Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc N ephrol 2000; 11:1656-1666.
13. Park EY, Seo MJ, Park JH. Effects of specific genes activating RAGE on polycystic kidney disease. Am J Nephrol 2010; 32:169-178.
14. D'Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010; 6:352-360.
15. Sadik NA, Mohamed WA, Ahmed MI. The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis. Mol Cell Biochem 2012; 359:73-81.
16. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108:261-268.
17. Wendt TM, T anji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162:1123-1137.
18. Fukami K, Cooper ME, Forbes JM. Agents in development for the treatment of diabetic nephropathy. Expert Opin Investig Drugs 2005; 14:279-294.
19. Fukami K, Yamagishi S, Coughlan MT, et al. Ra mipril inhibits AGE-RAGEinduced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. Diabetol Metab Syndr 2014; 6:86.
20. Suzuki D, Toyoda M, Yamamoto N, et al. Relationsh ip between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med 2006; 45:435-441.
21. Flyvbjerg A, Denner L, Schrijvers BF, et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004; 53:166-172.
22. Jensen LJ, Denner L, Schrijvers BF, et al. Renal effects of a neutralising RAGEantibody in long-term streptozotocin-diabetic mice. J Endocrinol 2006; 188:493-501.
23. Tesch G,Sourris KC,Summers S.A.,et al.Deletion of bone-marrow-derived receptor for AGEs (RA GE) improves renal function in an experimental mouse model of diabetes, Diabetologia 2014, 57,1977-1985.
24. Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004; 66:2137-2147.
25. Fukami K, Yamagishi S, Kaifu K, et al. Telmisartan inhibits AGE-induced podocyte damage and detachment. Microvasc Res 2013; 88:79-83.
26. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-1321.
27. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48:1-9.
28. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44:1957-1972.
29. Yamagishi S, Nakamura K, Matsui T, et al. Agents that blo ck advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008; 17:983-996.
30. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabet es 2008; 57:460-469.
31. Liebisch M, Bondeva T, Franke S, et al. Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression. Kid ney Int 2014; 86:103-117.
32. Jha JC, Gray SP, Barit D, et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase Nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 2014; 25:1237-1254.
33. Kaida Y, Fukami K, Matsui T, et al. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes 2013; 62:3241-3250.
34. Ojima A, Matsui T, Nakamura N, et al. DNA aptamer raised against advanced glycation end products (AGEs) improves glycemic control and decreases adipocyte size in fructose-fed rats by suppressing AGE-RAGE axis. Horm Metab Res 2014. [Epub ahead of print]
35. Khakurel S, Agrawal RK, Hada R. Pattern of end stage renal disease in a tertiary care center. JNMA J Nepal Med Assoc 2009; 48:126-130.
36. Wang XC, Liu CH, Chen YJ, et al. Clinical and pathological analysis of the kidney in patients with hypertensive nephropathy. Exp Ther Med 2013; 6:1243-1246.
37. Abel M, Ritthaler U, Zhang Y, et al. Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant 1995; 10:1662-1667.
38. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87:840-844.
39. Fukami K, Yamagishi SI, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des 2014; 20:2395-2402.
40. Yamagishi S, Maeda S, Matsui T, et al. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta 2012; 1820:663-671.
41. Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16:2976-2984.
42. Matsui T, Yamagishi S, Takeuchi M, et al. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Ph armacol Res 2010; 61:34-39.
43. Ishibashi Y, Matsui T, Ueda S, et al. Irbesartan inhibits advanced glycation end product-induced increase in asymmetric dimethylarginine level in mesangial cells throu gh its antioxidative properties. Int J Cardiol 2014; 176:1120-1122; doi: 10.1016/j.ijcard.2014.07.299. [Epub ahead of print]
44. Kambham N,Markowitz GS ,,Valeri AM,et al., Obesity-related glomerulopathy: an emerging epidemic, Kidney Int,2001, 59,1498-1509.
45. Chen HM, Liu ZH, Zeng CH, et al. Podocyte lesions in patients with obesityrelated glomerulopathy. Am J Kidney Dis 2006; 48:772-779.
46. Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for endstage renal disease. Ann Intern Med 2006; 144:21-28.
47. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633.
48. Dengel DR, Goldberg AP, Ma yuga RS, et al. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension 1996; 28:127-132.
49. Amin MN, Mosa AA, El-Shishtawy MM. Clinical study of advanced glycation end products in egyptian diabetic obese and nonobese patients. Int J Biomed Sci 2011; 7:191-200.
50. Hiras awa Y, Matsui Y, Yamane K, et al. Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction. Exp Anim 2008; 57:423-432.
51. Hagiwara S, G ohda T, Tanimoto M, et al. Effects of pyridoxamine (k-163) on glucose intolerance and obesity in high-fat diet c57bl/6j mice. Metabolism 2009; 58:934-945.
52. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929-939.
53. Lorenz G, Desai J, Anders HJ. Lupus nephritis: update on mechanisms of systemic autoimmunity and kidney immunopathology. Curr Opin Nephrol Hypertens 2014; 23:211-217.
54. Sun W, Jiao Y, Cui B, et al. Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Lab Invest 2013; 93:626-638.
55. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8:487-496.
56. Wen Z, Xu L, Chen X, et al. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol 2013; 190:5411-5422.
57. Ma CY, Jiao YL, Zhang J, et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-a and TNF-a in systemic lupus erythematosus. Rheumatol Int 2012; 32:395-402.
58. Abdulahad DA, Westra J, Bijzet J, et al. Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthri tis Res Ther 2012; 14:R184.
59. Martens HA, Nienhuis HL, Gross S, et al. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus 2012; 21:959-968.
60. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000; 130:88-98.
61. Owen WF , Hou FF, Stuart RO, et al. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int 1998; 53:1365-1373.
62. Miyata T, Hori O, Zhang J, et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathog enesis of dialysis-related amyloidosis. J Clin Invest 1996; 98:1088-1094.
63. Rysavá R, Kalousová M, Zima T, et al. Does renal function influence plasma levels of advanced glycation and oxidatio n protein products in patients with chronic rheumatic diseases complicated by secondary amyloidosis? Kidney Blood Press Res 2007; 30:1-7.
64. Rö cken C, Kientsch-Engel R, Mansfeld S, et al. Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis. Am J Pathol 2003; 162:1213-1220.
65. Anan I, Kiuru-Enari S, Obayashi K, et al. Investigation of AGE, thei r receptor and NF-kappaB activation and apoptosis in patients with ATTR and gelsolin amyloidosis. Histol Histopathol 2010; 25:691-699.
66. Lieske JC, Toback FG. Autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993; 3:1442-1450.
67. Bello-Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 2001; 60:37-45.
68. Novalic Z, van der Wal AM, Leonhard WN, et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 2012; 23:842-853.
69. P ark EY, Kim BH, Lee EJ, et al. Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease. J Biol Chem 2014; 289:9254-9262.
70. KDIGO Clinical practice guideline for acute kidney injury. Section 2: AKI definition. Kidney Int Suppl 2012; 2:19-36.
71. Uchino S, Kellum JA, Bellomo R, et al., Beginning and Ending Supportive Therapy for th e Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294:813-818.
72. Takasu O, Gaut JP, Watanabe E, et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med 2013; 187:509-517.
73. Brodska H, Malickova K, Valenta J, et al. Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis. Scand J Clin Lab Invest 2013; 73:650-660.
74. Y ang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101:296-301.
75. Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-1650.
76. Yamamoto Y, Harashima A, Sai to H, et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol 2011; 186:3248-3257.